| 1 | Multiomics identifies unique modulators of calf muscle |
|------------------|--|
| 2 | pathophysiology in peripheral artery disease and chronic kidney |
| 3 | disease |
| 4 | |
| 5 6 7 8 | Kyoungrae Kim ¹ , Trace Thome ¹ , Caroline Pass ¹ , Lauren Stone ¹ , Nicholas Vugman ¹ , Victoria Palzkill ¹ , Qingping Yang ¹ , Kerri A. O'Malley ² , Erik M. Anderson ² , Brian Fazzone ² , Feng Yue ^{3,5} , Scott A. Berceli ² , Salvatore T. Scali ² , Terence E. Ryan ^{1,4,5,#} |
| 9 | ¹ Department of Applied Physiology and Kinesiology |
| 10 | ² Department of Surgery |
| 11 | ³ Department of Animal Sciences |
| 12 | ⁴ Center for Exercise Science |
| 13 | ⁵ Myology Institute |
| 14 | The University of Florida, Gainesville, FL, USA |
| 15 16 17 | Running Head: Multiomics in PAD and CKD |
| 18 | *Correspondence: Terence E. Ryan, PhD: 1864 Stadium Rd, Gainesville, FL, 32611. Tel: 352-294-1700 |
| 19 | (office); email: <u>ryant@ufl.edu;</u> Twitter: @TerenceRyan_PhD |
| 20 | KEVIMORDS: peripheral artery disease repair uremia mitochondria muscle |
| 22 | NETWORDS. periprieral altery disease, renal, drenna, fillochondria, filuscie |
| 23 | Manuscript word count: 3900 |

- 24 Abstract word count: 346
- 25 Running head character count: 25
- 26 Number of references: 68
- 27 Number of Grayscale figures: 0
- 28 Number of color figures: 7
- 29 Number of tables: 1
- 30
- 31 Table and Figure count: 8
- 32

33 ABSTRACT

34

35 BACKGROUND: Chronic kidney disease (CKD) has emerged as a significant risk factor that accelerates 36 atherosclerosis, decreases muscle function, and increases the risk of amputation or death in patients 37 with peripheral artery disease (PAD). However, the modulators underlying this exacerbated 38 pathobiology are ill-defined. Recent work has demonstrated that uremic toxins are associated with limb 39 amputation in PAD and have pathological effects in both the limb muscle and vasculature. Herein, we 40 utilize multiomics to identify novel modulators of disease pathobiology in patients with PAD and CKD. 41 METHODS: A cross-sectional study enrolled four groups of participants: controls without PAD or CKD 42 (n=28), patients with PAD only (n=46), patients with CKD only (n=31), and patients with both PAD and 43 CKD (n=18). Both targeted (uremic toxins) and non-targeted metabolomics in plasma were performed 44 using mass spectrometry. Calf muscle biopsies were used to measure histopathology, perform bulk and 45 single-nucleus RNA sequencing (snRNAseq), and assess mitochondrial function. Differential gene and

46 metabolite analyses, as well as pathway and gene set enrichment analyses were performed.

47 **RESULTS:** Patients with both PAD and CKD exhibited significantly lower calf muscle strength and smaller
48 muscle fiber areas compared to controls and those with only PAD. Compared to controls, mitochondrial
49 function was impaired in CKD patients, with or without PAD, but not in PAD patients without CKD.

Plasma metabolomics revealed substantial alterations in the metabolome of patients with CKD, with significant correlations observed between uremic toxins (e.g., kynurenine, indoxyl sulfate) and both muscle strength and mitochondrial function. RNA sequencing analyses identified downregulation of mitochondrial genes and pathways associated with protein translation in patients with both PAD and CKD. Single nucleus RNA sequencing further highlighted a mitochondrial deficiency in muscle fibers along with unique remodeling of fibro-adipogenic progenitor cells in patients with both PAD and CKD, with an increase in adipogenic cell populations.

57 CONCLUSIONS: CKD significantly exacerbates ischemic muscle pathology in PAD, as evidenced by

58 diminished muscle strength, reduced mitochondrial function, and altered transcriptome profiles. The

59 correlation between uremic toxins and muscle dysfunction suggests that targeting these metabolites

60 may offer therapeutic potential for improving muscle health in PAD patients with CKD.

61

62 **ABBREVIATIONS**

- 63 CKD = chronic kidney disease; GFR = glomerular filtration rate; GSEA = gene set enrichment analysis;
- 64 OXPHOS = oxidative phosphorylation; PAD = peripheral arterial disease; ROS = reactive oxygen species;

65 snRNAseq = single nucleus RNA sequencing

66

67 INTRODUCTION

68 Peripheral arterial disease (PAD) is a condition characterized by atherosclerosis in the blood vessels of

69 the lower extremities, affecting approximately 8-12 million Americans, and is a leading cause of

70 cardiovascular mortality^{1,2}. Common risk factors for PAD include age, smoking, diabetes, hypertension,

and dyslipidemia. Notably, chronic kidney disease (CKD) is also strongly associated with PAD,

72 contributing to the development of atherosclerosis, decreased muscle function, and an increased risk of

amputation or death in patients with PAD³⁻⁹. Furthermore, CKD is linked to higher failure rates of both

rendovascular and open surgical revascularization procedures, which are commonly used in the

75 management of PAD^{3,10}. Recent work has reported a strong correlation between uremic metabolites—

76 accumulating in CKD—and the risk of adverse limb events in patients with PAD¹¹. Both PAD and CKD

have been associated with skeletal muscle myopathy¹²⁻²⁴, suggesting that muscle tissue may be a key

site where these two diseases intersect. Importantly, muscle function and exercise performance have

been established as strong predictors of morbidity and mortality in patients with PAD^{13,15,25-27}. Despite 79 80 these associations, the mechanisms underlying the exacerbated skeletal myopathy in patients with both 81 PAD and CKD remain poorly understood. A deeper analysis could reveal novel targets for preventing or 82 ameliorating muscle pathology in these patients. This cross-sectional study aimed to characterize the 83 impact of PAD and CKD on skeletal muscle pathology by comparing calf muscle strength, mitochondrial 84 function, and histopathology in four groups: 1) PAD patients, 2) PAD with CKD patients, 3) CKD patients, and 4) non-PAD and non-CKD controls. A multiomic approach, including bulk and single nucleus RNA 85 86 sequencing of calf muscle specimens and both targeted and untargeted plasma metabolomics, was 87 employed to identify novel regulators of skeletal muscle pathology

88

89 MATERIALS AND METHODS. Detailed descriptions of the materials and experimental procedures can be 90 found in the Expanded Material and Methods section of the Supplemental Material. The data 91 supporting the conclusions of this study are available from the corresponding author. A Major Resources 92 Table is available in the Supplemental Material.

93

Study Population. This was a cross-sectional study involving participants without PAD or CKD, those with 94 95 PAD only, those with CKD only, and those with both PAD and CKD. Participants were recruited through 96 UF Health and the Malcom Randall VA Medical Centers in Gainesville, FL. This study was approved by 97 the institutional review boards at the University of Florida and the Malcom Randall VA Medical Center 98 (Protocol IRB201801553). All study procedures were carried out according to the Declaration of Helsinki 99 and participants were fully informed about the research and informed consent was obtained. Patients 100 with a normal ABI (greater than 0.9) or those with an abnormal ABI (less than 0.9) indicating a diagnosis 101 of PAD with a Rutherford Stage between 3-5 set as inclusion criteria. Patients with non-atherosclerotic 102 occlusive disease were excluded (acute limb ischemia, vasculitis, Buerger's disease, etc.). Inclusion 103 criteria for CKD included an estimated glomerular filtration rate (eGFR) between 15 and 50 104 mL/min/1.73m² for greater than three months. Medical history, race, smoking history, and 105 demographics were obtained by self-report. Co-existing medical conditions and medication usage was 106 obtained through review of medical records. Non-PAD controls were recruited within the University of 107 Florida Hospital System and Malcom Randall VA medical center and were free from peripheral vascular 108 disease.

109

<u>Calf muscle testing</u>. A detailed description of analysis of calf muscle strength, muscle biopsy technique,
 mitochondrial function, muscle histopathology, and bulk and single nucleus RNA sequencing can be
 found on the Supplemental Material.

113

114 Plasma Metabolomics. A blood sample was obtained from a peripheral antebrachial vein using EDTA 115 tubes and was subsequently centrifuged and plasma was frozen at -80°C until analysis. Sample underwent untargeted metabolomic analysis (Global Discovery platform) at a core laboratory using a 116 117 well-validated Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-118 MS/MS) platform (Metabolon, Inc.; Morrisville, NC, USA). The platform combines multiple sample 119 preprocessing protocols and a comprehensive reference library, resulting in quantitative estimates of 120 metabolite abundance covering a broad spectrum of chemical classes, including amino acids, 121 carbohydrates, lipids, nucleotides, peptides and vitamins, xenobiotic substances, and pharmaceutical 122 and food preservative compounds. A detailed description of the analytical protocol, metabolite 123 identification, and normalization procedures is included in the Supplementary Methods. Samples were 124 randomized across the platform run with quality control samples spaced evenly among the injections. 125 Metabolite abundance was estimated from the area under the curve for annotated peaks in the mass 126 spectrogram (mass spectral counts) and was normalized for batch and run day. Samples were also 127 processed for targeted metabolomic analysis of kynurenine, tryptophan, 3-indoxyl sulfate, p-cresol 128 sulfate (pCS), 4-ethylphenyl sulfate (4-EPS), 3-indolelactic acid, and 3-indolepropionic acid in which quantitative analysis was performed using standard curves for each metabolite. 129

130

131 Statistical analysis. Normality of data was tested with the Shapiro-Wilk test and inspection of QQ plots. 132 Data involving comparisons of normally distributed data from groups were analyzed using a one-way 133 ANOVA. Data involving comparisons of non-normally distributed data from groups were analyzed using 134 a Kruskal-Wallis test. When appropriate, Tukey's posthoc testing was used to assess differences between groups. To assess relationships between two variables, Pearson correlation analysis was 135 136 employed. Chi-Square analysis was used to determine differences in population proportions for relevant 137 clinical characteristics. For bulk and snRNAseq, the Benjamini–Hochberg method was used to calculate 138 false discovery rate corrected *P*-values. In all cases, P < 0.05 was considered statistically significant. All

statistical testing was conducted using R-studio, Python, or GraphPad Prism software (version 9.0). Data
 are presented as the mean ± standard deviation unless otherwise specified.

141

142 **RESULTS**

Patients with PAD and CKD have significantly lower calf muscle strength and myofiber areas. Fourty-143 144 six patients with PAD with normal kidney function, 18 patients with PAD and CKD, 31 patients with CKD only (no PAD), and 28 people with PAD or CKD were included in this study (N=123 total). The participant 145 146 characteristics are shown in Table 1. Calf muscle (plantar flexors) strength was significantly lower in 147 patients with PAD (P=0.0409), patients with CKD (P=0.0193), and patients with PAD and CKD (P<0.0001) 148 when compared with controls that were free from PAD and CKD (Figure 1A). PAD patients with CKD had 149 significantly lower calf muscle strength than PAD patients with normal kidney function (P=0.0103). After 150 normalizing calf muscle strength to body weight, significant differences remained for PAD vs. PAD+CKD 151 and control vs. PAD+CKD comparisons. Analysis of the mean myofiber cross sectional area demonstrated 152 that PAD, CKD, and PAD+CKD groups had significantly smaller Type I and Type II myofibers compared to 153 control participants (Figure 1B,C), however, the relative proportion fiber types was not significantly 154 different (Figure 1D). Within the cohort, a significant correlation (Pearson r = 0.3160, P=0.0390) was 155 observed between calf muscle strength and the mean myofiber area (Figure 1E). These findings reveal a

156 clear deterioration in muscle function in PAD patients with CKD.

157

158 Calf muscle mitochondrial function is negatively impacted by CKD, but not PAD alone. High-resolution 159 respirometry and fluorescence spectroscopy were used to assess muscle mitochondrial function in 160 freshly permeabilized muscle fiber bundles using a creatine kinase clamp to perform a 'mitochondrial 161 stress test" across a range of physiologically relevant energy demands (Figure 2A). Oxygen consumption 162 (JO₂) was lower in patients with CKD and PAD+CKD, but nearly identical in patients with only PAD and control participants (Figure 2B). Quantification of the slope of oxygen consumption vs. energy demand 163 164 (ΔG_{ATP}) , termed OXPHOS conductance, represents the sensitivity of the mitochondrial system to respond to increases in energy demand. In this case, a higher OXPHOS conductance is interpreted as better 165 166 mitochondrial function. OXPHOS conductance was not different between controls and PAD patients with 167 normal kidney function (P=0.97), however CKD patients without PAD and PAD+CKD patients had

significantly lower OXPHOS conductance compared to controls (P=0.0123 and P=0.0054 respectively).

169 PAD+CKD patients had significantly lower OXPHOS conductance than PAD patients without CKD (Figure

170 **2C**). Citrate synthase activity, a biomarker of mitochondrial content in skeletal muscle, was not

significantly lower in CKD (P=0.095) and PAD+CKD (P=0.63) groups compared to controls (Figure 2D).

172 Mitochondrial H₂O₂ emission was not significantly different between groups across the levels of energy

demand (Figure 2E) or without energy demand (Figure 2F) when fueled by

174 pyruvate/malate/octanoylcarnitine. When fueled with succinate in the absence of energy demand with

175 or without inhibitors of the matrix antioxidant systems, PAD+CKD muscles had lower mitochondrial H₂O₂

176 emission than controls (Figure 2G). Succinate dehydrogenase (SHD) enzyme activity assessed

177 histochemically on thin sections of muscle showed a lower SDH activity in CKD and PAD+CKD groups

178 (Figure 2H).

179

180 **CKD significantly alters the plasma metabolome.** Next, we performed targeted metabolomics to 181 quantify the absolute abundance of known uremic toxins including 3-indoxyl sulfate, p-cresol sulfate 182 (pCS), 4-ethylphenyl sulfate (4-EPS), 3-indolelactic acid, 3-indolepropionic acid, kynurenine (L-Kyn), 183 tryptophan (Trp), and the L-Kyn/Trp ratio in plasma of this cohort. As expected, CKD and PAD+CKD 184 groups had significantly higher levels of all these uremic toxins (Figure 3A). No differences were found 185 between controls and patients with PAD only. We also performed global untargeted metabolomics on 186 the cohort which resulted in identification of 1557 metabolites/biochemicals, 1277 of which were 187 identified in the compound library and 277 with unknown identity (Figure 3B). Principal component 188 analysis revealed two relatively distinct clusters which separate the patients with and without CKD 189 (Figure 3C). Compared to controls, patients with PAD had relatively similar plasma metabolomes with 99 190 differentially abundant metabolites (46 up and 53 down). In contrast, patients with CKD had 763 191 differentially abundant metabolites compared to controls (623 up and 140 down). Consistent with these 192 findings, PAD+CKD patients had 578 differentially abundant metabolites (521 up and 57 down) 193 compared to PAD patients. A heatmap with hierarchical clustering for all patients and metabolites is 194 shown in Figure 3D. A Venn diagram showing the shared and distinct numbers of differentially abundant 195 metabolites across comparisons is shown in Figure 3E. Pathway analysis revealed three main classes of 196 metabolites were impacted by disease classification including "Uremic Toxins", "Tissue Remodeling", 197 and Microbiome-related metabolites" (Supplemental Figure 1). The complete metabolomics dataset 198 and pathway analysis can be found in Supplemental Datasets 1 and 2 respectively.

199

| 200 | Skeletal muscle mitochondrial function and calf muscle strength are negatively correlated with |
|-----|---|
| 201 | tryptophan-derived uremic toxins. Previous studies have reported that tryptophan-derived uremic |
| 202 | toxins, such as indoxyl sulfate and kynurenine, were negatively associated with muscle health and |
| 203 | mitochondrial function ^{23,28-31} . Thus, we perform Pearson correlation analyses to determine if |
| 204 | mitochondrial function (OXPHOS conductance) or muscle strength were related to these uremic toxins. |
| 205 | Strikingly, kynurenine, L-Kyn/Trp ratio, and indoxyl sulfate had significant inverse correlations with both |
| 206 | mitochondrial function (Figure 4A) and calf muscle strength (Figure 4B) in this cohort. |

207

208 Whole muscle and single nucleus RNA sequencing identifies transcriptome changes in PAD patients 209 with CKD. To understand how CKD impacts the skeletal muscle transcriptome, we performed bulk RNA 210 sequencing on total RNA isolated from a portion of the gastrocnemius muscle biopsy of 88 patients. 211 Gene expression was quantified for 24,871 genes. Comparing PAD to controls, 52 differentially 212 expressed genes were detected (12 downregulated and 40 upregulated) (Supplemental Figure 2A-D). 213 Comparing CKD to controls, 602 differentially expressed genes were detected (300 downregulated and 214 302 upregulated) (Supplemental Figure 2E-H). Comparing patients with PAD to those with PAD+CKD, 215 partial least squares discriminant analysis (PLS-DA) showed two distinct clusters (Figure 5A). Patients 216 with PAD+CKD had 361 differentially expressed genes from patients with only PAD (189 downregulated 217 and 172 upregulated) (Figure 5B). GSEA in this comparison revealed that down regulated genes were 218 significantly enriched in pathways related to "cellular respiration" and "oxidative phosphorylation", 219 whereas significantly upregulated genes were enriched in pathways related to "cytoplasmic translation", 220 "ribosome biogenesis", and "rRNA processing" (Figure 5C). Full results of the DEG and GSEA analysis for 221 each comparison can be found in Supplemental Dataset 3.

Because there are many cell types within skeletal muscle, we next used single nucleus RNA sequencing to enhance the resolution of analysis of calf muscle. 61,586 nuclei were analyzed from 20 PAD patients and 12 patients with PAD+CKD. Unsupervised clustering identified 14 clusters representing the major cell types expected in skeletal muscle (**Figure 5D**). Compared to PAD patients without CKD, PAD+CKD patients had fewer Type I myofiber nuclei and a higher proportion of nuclei that represented NMJ/regenerating myonuclei, fibro-adipogenic progenitor cells (FAPs), endothelial cells, and macrophages (**Figure 5E**). Top marker genes for each cell/nuclei type are shown in **Figure 5F**. DEG

229 analysis in the myofiber nuclei populations (Figure 5G,H) revealed a significant number of differentially 230 expressed genes within each cluster, however Type I myofiber nuclei had the largest number of DEGs. 231 With knowledge that bulk RNAseq GSEA analysis identified mitochondria as a downregulated biological 232 process, we generated a mitochondrial gene expression score which represents the overall 233 mitochondrial gene expression. This analysis confirmed all myonuclei populations in PAD+CKD muscles 234 displayed a mitochondrial deficiency, although Type I myofiber nuclei appeared to be most affected (Figure 5I). GSEA analysis from myonuclei had common pathways related to "aerobic respiration" in the 235 236 downregulated DEGs (Figure 5J). Additional DEG, GSEA, and top marker genes for other cell types can be 237 found in Supplemental Dataset 4.

238

239 Fibro-adipogenic progenitor (FAPs) cells are uniquely remodeled in muscle from patients with PAD 240 and CKD. Next, we investigated how CKD impact FAPs, a resident mesenchymal stem cell population 241 that has been shown to be critical for muscle regeneration, were impacted by CKD in patients with PAD. 242 Subclustering of FAPs revealed eight distinct cell populations including pro-fibrotic, adipogenic, and MME+ clusters³² (Figure 6A). PAD patients with CKD had a higher abundance of adipocyte/adipogenic 243 244 FAPs (16% vs. 5.6%) and a unique population of ADAM12⁺ FAPs that was only present in PAD+CKD (Figure 6B). We used the Palantir algorithm³³ to characterize differences in cell fate between PAD and 245 246 PAD+CKD FAPs. In patients with only PAD, a single terminate state representing the low abundance 247 adipocyte lineage was observed, whereas two clear terminal states were seen in PAD+CKD FAPs 248 (adipocyte and MME⁺) along with a substantially higher differentiation potential in other populations 249 compared with FAPs from PAD patients (Figure 6C). Trajectory inference uncovered and additional 250 pathway for FAP differentiation in patients with PAD+CKD producing the ADAM12⁺ population (Figure 251 **6D**). Normalized gene expression showed the ADAM12⁺ FAP population was enriched for myokines IL6 252 and IGF1, whereas the pro-fibrotic FAPs displayed high expression of TGFB1 and COL1A1 (Figure 6E). 253 Expression of branch-specific genes along pseudotime are shown in Figure 6F. Other notable cell types that displayed significant transcriptome and population differences in PAD+CKD included macrophages 254 (Supplemental Figure 3) and endothelial cells (Supplemental Figure 4). 255

256

257 CKD influences intercellular communication in calf muscle from patients with PAD. To explore how the
 258 presence of CKD influences intercellular communication, we employed CellChat³⁴ to assess inferred

259 ligand-receptor interactions. Circle plots depicting the global intercellular communication are shown in 260 Figure 7A, where the line width represents the communication strength. While the number of 261 interactions was lower in PAD+CKD compared to PAD (2920 vs. 3552), the strength of those interactions 262 was greater (Figure 7B). Comparisons of the major 'senders' and 'receivers' identified FAPs and 263 adipocytes as the primary 'senders' whereas vascular populations including endothelial, lymphatic 264 endothelial, and smooth muscle/pericyte cells were determined to be the major 'receivers' (Figure 7C). 265 Significant signaling pathways between PAD and PAD+CKD were identified according to variations in 266 information flow within inferred signaling networks (Figure 7D)

267

268 DISCUSSION

269 Patients with PAD often present with one or more comorbid conditions that worsen ischemic pathology 270 and increase the risk of an adverse limb event. Recent studies have clearly demonstrated that CKD may be one of the strongest risk factors for poor outcomes in PAD^{11,35}. In this cross-sectional study, we 271 272 leveraged state-of-the-art multiomic analyses and mitochondrial and muscle function assessments to 273 dissect how CKD impacts calf muscle pathophysiology in patients with PAD. Compared to non-PAD 274 control with normal kidney function, patients with only PAD, patients with only CKD, and patients with 275 both PAD and CKD had significantly weaker calf muscles and muscle fiber areas (Figure 1). Compared to 276 patients with PAD, those with PAD and CKD were also significantly weaker and had smaller muscle fiber 277 areas demonstrating that CKD exacerbates the ischemic myopathy in PAD. Skeletal muscle 278 mitochondrial function was significantly impaired in patients with CKD only and those with PAD and CKD 279 (Figure 2). Interestingly, no differences were observed between patients with PAD and the non-PAD 280 controls. A significant negative correlation was found between the levels of indoxyl sulfate, L-281 Kynurenine, or the L-Kyn/Trp ratio and both mitochondrial function and muscle strength (Figure 4). This 282 observation agrees with previous studies that reported similar associations in rodents with and without 283 CKD^{23,28-30}, implicating uremic toxins as strong drivers of muscle impairment in CKD. These findings also 284 agree with those of preclinical studies in which limb function of animals with CKD subjected to hindlimb 285 ischemia was impaired compared to animals with normal kidney function subjected to hindlimb ischemia ^{11,30,36-38}. Mechanistically, recent studies have shown that the aryl hydrocarbon receptor is 286 required for tryptophan-derived uremic toxins to impair skeletal muscle function and ischemic 287 angiogenesis^{11,30,38}. Beyond uremic toxins, tobacco smoking products also contain ligands that activate 288 the aryl hydrocarbon receptor in skeletal muscle^{39,40}, namely 2,3,7,8-Tetrachlorodibenzodioxin (known 289

as TCDD), and smoking is considered the strongest risk factor for PAD suggesting this pathway could
 have a much broader impact of calf muscle pathophysiology in patients with PAD. In totality, these
 findings suggest that CKD induces muscle mitochondrial dysfunction in patients with and without PAD,
 potentially through mechanisms involving uremic toxins like indoxyl sulfate and kynurenines that
 activate the aryl hydrocarbon receptor.

295

296 Calf muscle mitochondrial OXPHOS was ~40% lower in patients with CKD than those without (Figure 2). 297 This profound impact of CKD on skeletal muscle mitochondrial function and content aligns with previous studies^{21,24,41-43}. In contrast, there were no differences between non-PAD controls and patients with PAD 298 299 that had normal kidney function. This lack of difference in mitochondrial respiratory function is consistent with some previous studies⁴⁴⁻⁴⁶, but not all⁴⁷⁻⁵⁰, that used similar methodologies. The lack of 300 301 agreement across these studies may be due to modest sample sizes and differences in patient 302 characteristics. Nonetheless, there is accumulating evidence that markers of mitochondrial content 303 (mtDNA copy number, electron transport system complex abundance, citrate synthase activity, etc.) are increased in the calf muscle of patients with PAD^{17,51,52}. This compensatory response is likely related to 304 the hypoxia-induced energetic stress response that occurs within the calf muscles of PAD¹⁷. The striking 305 impact of CKD on calf muscle mitochondrial health was also supported by the down regulation of 306 307 mitochondrial gene expression observed in both bulk and single nucleus RNA sequencing analyses 308 comparing PAD and PAD+CKD groups (Figure 5). In both diseases calf muscle mitochondrial function correlates with walking performance^{24,52,53}. Further investigation is needed to determine whether 309 interventions that improve or optimize calf muscle mitochondrial function can lead to improvements in 310 311 walking performance in these patients.

312

Calf muscle from patients with PAD and CKD displayed a unique remodeling of a resident mesenchymal stem population called fibro-adipogenic progenitor cells (FAPs). These resident multipotent stem cells are located within the muscle interstitium where they have a heavy presence surrounding blood vessels. They have numerous differentiation paths with the two main fates being adipocytes or myofibroblasts⁵⁴. Compared to PAD patients with normal kidney function, those with PAD and CKD had ~2.5-fold increase in adipocytes according to snRNAseq results. This accumulation of intramuscular adipose tissue is a form of myosteatosis which has been shown to impair muscle function^{55,56} and regeneration from injury⁵⁷⁻⁵⁹.

This phenotype has been observed independently in CKD⁶⁰ and PAD⁶¹. Considering that muscle function is strongly associated with mortality in PAD^{13,15} and CKD⁶², further studies are needed to determine if therapies the prevent or mitigate intramuscular adipose tissue in these conditions can improve muscle function and lower mortality risk.

324

325 Plasma metabolomics analyses revealed the wide-ranging impact on the plasma metabolome in patients 326 with CKD (>500 differentially abundant biochemicals). In contrast, we found relatively few metabolites 327 (99) that were differentially abundant between non-PAD controls and PAD patients. Only a few studies have examined the plasma metabolomes in patients with PAD^{11,63-65}, with the majority of studies 328 329 reporting associations between amino acid metabolites, namely kynurenine and tryptophan, as well as indoles, and the risk of developing PAD or having adverse limb events^{11,64,65}. The link between these 330 331 uremic toxins and PAD risk may be indicative of the incidence of renal dysfunction in those study 332 populations despite some studies excluding patients with diagnosed kidney disease. Alternatively, the 333 source of kynurenines and indoles could be related to levels of systemic inflammation or dysregulation of the gut microbiome⁶⁶⁻⁶⁸, both areas that have been underexplored in PAD. The highly overlapping 334 335 plasma metabolomes between the non-PAD controls and patients with PAD may also be indicative of 336 how well these groups were matched for co-morbid conditions, risk factors, and medication usage 337 (Table 1). Additionally, the plasma metabolome in PAD is not likely to match the complex 338 microenvironment within the affected limb where local metabolite alterations are presumed to be much 339 greater than those reflected from a systemic plasma sample. Local sample collection from the diseased 340 limb followed by subsequent metabolomic analyses could reveal the full impact of limb ischemia on 341 metabolite exchange in tissues below of the occlusive lesion.

342

Given that our cohort of patients were restricted to moderate CKD (Stage 3b-4) and moderate-severe PAD (Rutherford Stage 3-5), our analyses may not be representative of the full spectrum of either disease. However, this design was chosen to enable deep phenotyping and multiomic analyses across the four groups. Additional studies should be performed to evaluate the reported relationships across the spectrum of both PAD and CKD. Although this patient cohort contained 39% female participants, we have not performed sex comparisons due to the relatively small sample sizes within each group for such a comparison. Future analyses of these data could be performed to begin understanding how biological

350 sex may alter the impact of CKD on PAD pathobiology. Additionally, while the control group was 351 relatively well matched for clinical and physical characteristics, there were some comorbid conditions 352 that were more prevalent in the PAD and CKD groups including hypertension and diabetes. It is 353 important to note that these two conditions are among the strongest risk factors for developing CKD. 354 This was a cross-sectional study design and longitudinal analyses were not performed. Thus, analyses 355 exploring how specific outcomes change across time and whether they impact adverse limb events, 356 morbidity, or mortality risk could not be performed. Despite these limitations, this study provides a 357 robust and in-depth analysis of the skeletal myopathy in patients with PAD and CKD using physiological 358 testing and multiomic analyses which identify pathways and processes that may have potential for 359 interventional approaches that have promise to improve muscle function in these patients.

360

361 CONCLUSIONS

This study demonstrates that chronic kidney disease significantly worsens the ischemic limb myopathy in patients with PAD evidenced by lower calf muscle strength, muscle fiber sizes, and mitochondrial function. Multiomic analyses of calf muscle revealed a striking deficiency in myonuclear gene expression related to mitochondria and protein translation specifically in patients with both PAD and CKD, compared to those with only PAD. The significant correlation between plasma uremic toxin levels and both calf muscle strength and mitochondrial function suggests that therapeutic strategies aimed at reducing uremic toxins may hold promise for improving muscle health in patients with CKD.

369

- 370 Sources of Funding: This study was supported by National Institutes of Health (NIH) grants R01-
- 371 HL149704 and HL171050 (T.E.R.). S.T.S. was supported by NIH grant R01HL148597. S.A.B. was supported
- by NIH grant R01DK119274. K.K. was supported by the American Heart Association grant POST903198.
- T.T. was supported by NIH grant F31-DK128920. V.R.P. was supported by the American Heart
- Association grant 24PRE1193999. C.P. was supported by the American Heart Association grant

375 24PRE1196311.

376

377 Disclosures: None.

378

379 Supplemental Material:

- 380 Expanded Materials and Methods
- 381 Supplemental Figures 1-4
- 382 Supplemental Dataset 1 (metabolomics).XLSX
- 383 Supplemental Dataset 2 (metabolomics pathway).XLSX
- 384 Supplemental Dataset 3 (bulk RNA).xlsx
- 385 Supplemental Dataset 4 (snRNA).xlsx
- 386

387 References

- Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. *J Am Geriatr Soc*. 2007;55:583-589. doi: 10.1111/j.1532-5415.2007.01123.x
- Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE,
 Sampson UK, Williams LJ, Mensah GA, et al. Comparison of global estimates of prevalence and
 risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.
 Lancet. 2013;382:1329-1340. doi: 10.1016/S0140-6736(13)61249-0
- Heideman PP, Rajebi MR, McKusick MA, Bjarnason H, Oderich GS, Friese JL, Fleming MD,
 Stockland AH, Harmsen WS, Mandrekar J, et al. Impact of Chronic Kidney Disease on Clinical
 Outcomes of Endovascular Treatment for Femoropopliteal Arterial Disease. *J Vasc Interv Radiol*.
 2016;27:1204-1214. doi: 10.1016/j.jvir.2016.04.036
- 4. Kaminski MR, Raspovic A, McMahon LP, Lambert KA, Erbas B, Mount PF, Kerr PG, Landorf
 401 KB. Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional
 402 observational study. *BMC Nephrol*. 2017;18:293. doi: 10.1186/s12882-017-0711-6
- 403 5. O'Hare AM, Sidawy AN, Feinglass J, Merine KM, Daley J, Khuri S, Henderson WG, Johansen
 404 KL. Influence of renal insufficiency on limb loss and mortality after initial lower extremity
 405 surgical revascularization. *J Vasc Surg*. 2004;39:709-716. doi: 10.1016/j.jvs.2003.11.038
- 406 6. Lacroix P, Aboyans V, Desormais I, Kowalsky T, Cambou JP, Constans J, Bura Riviere A,
 407 investigators C. Chronic kidney disease and the short-term risk of mortality and amputation in
 408 patients hospitalized for peripheral artery disease. *J Vasc Surg.* 2013;58:966-971. doi:
 409 10.1016/j.jvs.2013.04.007

| 410 411 412 | 7. | O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. <i>Journal of the American Society of Nephrology : JASN</i> . 2005;16:514-519. doi: 10.1681/ASN.2004050409 |
|--------------------------|-----|--|
| 413 414 415 | 8. | Pasqualini L, Schillaci G, Pirro M, Vaudo G, Siepi D, Innocente S, Ciuffetti G, Mannarino E. Renal dysfunction predicts long-term mortality in patients with lower extremity arterial disease. <i>J</i> <i>Intern Med.</i> 2007;262:668-677. doi: 10.1111/j.1365-2796.2007.01863.x |
| 416 417 418 | 9. | Liew YP, Bartholomew JR, Demirjian S, Michaels J, Schreiber MJ, Jr. Combined effect of chronic kidney disease and peripheral arterial disease on all-cause mortality in a high-risk population. <i>Clin J Am Soc Nephrol.</i> 2008;3:1084-1089. doi: 10.2215/CJN.04411007 |
| 419 420 421 | 10. | Patel VI, Mukhopadhyay S, Guest JM, Conrad MF, Watkins MT, Kwolek CJ, LaMuraglia GM, Cambria RP. Impact of severe chronic kidney disease on outcomes of infrainguinal peripheral arterial intervention. <i>J Vasc Surg.</i> 2014;59:368-375. doi: 10.1016/j.jvs.2013.09.006 |
| 422 423 424 425 | 11. | Arinze NV, Yin WQ, Lotfollahzadeh S, Napoleon MA, Richards S, Walker JA, Belghasem M, Ravid JD, Kamel MH, Whelan SA, et al. Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease. <i>J Clin Invest</i> . 2022;132. doi: ARTN e142260 |
| 426 | | 10.1172/JCI142260 |
| 427 428 429 430 | 12. | McDermott MM, Criqui MH, Greenland P, Guralnik JM, Liu K, Pearce WH, Taylor L, Chau CL, Celic L, Woolley C, et al. Leg strength in peripheral arterial disease: Associations with disease severity and lower-extremity performance. <i>Journal of Vascular Surgery</i> . 2004;39:523-530. doi: 10.1016/j.jvs.2003.08.038 |
| 431 432 433 | 13. | Singh N, Liu K, Tian L, Criqui MH, Guralnik JM, Ferrucci L, Liao Y, McDermott MM. Leg strength predicts mortality in men but not in women with peripheral arterial disease. <i>J Vasc Surg.</i> 2010;52:624-631. doi: 10.1016/j.jvs.2010.03.066 |
| 434 435 436 437 | 14. | Garg PK, Liu K, Ferrucci L, Guralnik JM, Criqui MH, Tian L, Sufit R, Nishida T, Tao HM, Liao YH, et al. Lower Extremity Nerve Function, Calf Skeletal Muscle Characteristics, and Functional Performance in Peripheral Arterial Disease. <i>J Am Geriatr Soc.</i> 2011;59:1855-1863. doi: 10.1111/j.1532-5415.2011.03600.x |
| 438 439 440 | 15. | McDermott MM, Liu K, Tian L, Guralnik JM, Criqui MH, Liao Y, Ferrucci L. Calf muscle characteristics, strength measures, and mortality in peripheral arterial disease: a longitudinal study. <i>J Am Coll Cardiol</i> . 2012;59:1159-1167. doi: 10.1016/j.jacc.2011.12.019 |
| 441 442 443 | 16. | McDermott MM, Ferrucci L, Gonzalez-Freire M, Kosmac K, Leeuwenburgh C, Peterson CA, Saini S, Sufit R. Skeletal Muscle Pathology in Peripheral Artery Disease A Brief Review. <i>Arterioscl Throm Vas.</i> 2020;40:2577-2585. doi: 10.1161/Atvbaha.120.313831 |
| 444 445 | 17. | Ferrucci L, Candia J, Ubaida-Mohien C, Lyaskov A, Banskota N, Leeuwenburgh C, Wohlgemuth S, Guralnik JM, Kaileh M, Zhang D, et al. Transcriptomic and Proteomic of Gastrocnemius |

| ges |
|-----------------|
| |
| |
| |
| re |
| ooq l are |
| |
| emic |
| arb |
| ial |
| ng n .060 |
| ISC |
| |

| 480 481 482 | 28. | Thome T, Kumar RA, Burke SK, Khattri RB, Salyers ZR, Kelley RC, Coleman MD, Christou DD, Hepple RT, Scali ST, et al. Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease. <i>Jci Insight</i> . 2021;6. |
|---------------------------------|-----|---|
| 483 484 485 | 29. | Palzkill VR, Thome T, Murillo AL, Khattri RB, Ryan TE. Increasing plasma L-kynurenine impairs mitochondrial oxidative phosphorylation prior to the development of atrophy in murine skeletal muscle: A pilot study. <i>Frontiers in physiology</i> . 2022;13. doi: ARTN 992413 |
| 486 | | 10.3389/fphys.2022.992413 |
| 487 488 489 490 | 30. | Balestrieri N, Palzkill V, Pass C, Tan J, Salyers ZR, Moparthy C, Murillo A, Kim K, Thome T, Yang Q, et al. Activation of the Aryl Hydrocarbon Receptor in Muscle Exacerbates Ischemic Pathology in Chronic Kidney Disease. <i>Circulation research</i> . 2023;133:158-176. doi: 10.1161/CIRCRESAHA.123.322875 |
| 491 492 493 494 | 31. | Hetherington-Rauth M, Johnson E, Migliavacca E, Parimi N, Langsetmo L, Hepple RT, Grzywinski Y, Corthesy J, Ryan TE, Ferrucci L, et al. Nutrient metabolites associated with low D3Cr muscle mass, strength, and physical performance in older men. <i>J Gerontol A Biol Sci Med Sci</i> . 2023. doi: 10.1093/gerona/glad217 |
| 495 496 497 498 | 32. | Fitzgerald G, Turiel G, Gorski T, Soro-Arnaiz I, Zhang J, Casartelli NC, Masschelein E, Maffiuletti NA, Sutter R, Leunig M, et al. MME+ fibro-adipogenic progenitors are the dominant adipogenic population during fatty infiltration in human skeletal muscle. <i>Commun Biol.</i> 2023;6. doi: ARTN 111 |
| 499 | | 10.1038/s42003-023-04504-y |
| 500 501 502 | 33. | Setty M, Kiseliovas V, Levine J, Gayoso A, Mazutis L, Pe'er D. Characterization of cell fate probabilities in single-cell data with Palantir. <i>Nature biotechnology</i> . 2019;37:451-460. doi: 10.1038/s41587-019-0068-4 |
| 503 504 505 | 34. | Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using CellChat. <i>Nat Commun.</i> 2021;12:1088. doi: 10.1038/s41467-021-21246-9 |
| 506 507 508 509 510 | 35. | Amlani V, Ludwigs K, Rawshani A, Thuresson M, Falkenberg M, Smidfelt K, Nordanstig J. Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb Peripheral Arterial Disease: A Nationwide Observational Study(bigstar). <i>European journal of</i> <i>vascular and endovascular surgery : the official journal of the European Society for Vascular</i> <i>Surgery</i> . 2024. doi: 10.1016/j.ejvs.2024.07.041 |
| 511 512 513 | 36. | Jacobi J, Porst M, Cordasic N, Namer B, Schmieder RE, Eckardt KU, Hilgers KF. Subtotal nephrectomy impairs ischemia-induced angiogenesis and hindlimb re-perfusion in rats. <i>Kidney Int</i> . 2006;69:2013-2021. doi: 10.1038/sj.ki.5000448 |
| 514 515 | 37. | Berru FN, Gray SE, Thome T, Kumar RA, Salyers ZR, Coleman M, Dennis L, O'Malley K, Ferreira LF, Berceli SA, et al. Chronic kidney disease exacerbates ischemic limb myopathy in |

| 516 517 | | mice via altered mitochondrial energetics. <i>Sci Rep.</i> 2019;9:15547. doi: 10.1038/s41598-019-52107-7 |
|--------------------------|-----|--|
| 518 519 520 | 38. | Palzkill VR, Tan J, Yang Q, Morcos J, Laitano O, Ryan TE. Deletion of the aryl hydrocarbon receptor in endothelial cells improves ischemic angiogenesis in chronic kidney disease. <i>Am J Physiol Heart Circ Physiol</i> . 2024;326:H44-H60. doi: 10.1152/ajpheart.00530.2023 |
| 521 522 523 524 | 39. | Thome T, Miguez K, Willms AJ, Burke SK, Chandran V, de Souza AR, Fitzgerald LF, Baglole C, Anagnostou ME, Bourbeau J, et al. Chronic aryl hydrocarbon receptor activity phenocopies smoking-induced skeletal muscle impairment. <i>J Cachexia Sarcopenia Muscle</i> . 2022;13:589-604. doi: 10.1002/jcsm.12826 |
| 525 526 527 528 | 40. | Fitzgerald LF, Lackey J, Moussa A, Shah SV, Castellanos AM, Khan S, Schonk M, Thome T, Salyers ZR, Jakkidi N, et al. Chronic aryl hydrocarbon receptor activity impairs muscle mitochondrial function with tobacco smoking. <i>J Cachexia Sarcopenia Muscle</i> . 2024;15:646-659. doi: 10.1002/jcsm.13439 |
| 529 530 531 | 41. | Bittel DC, Bittel AJ, Varadhachary AS, Pietka T, Sinacore DR. Deficits in the Skeletal Muscle Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to Functional Decline. <i>Diabetes</i> . 2021;70:1130-1144. doi: 10.2337/db20-0688 |
| 532 533 534 535 | 42. | Xu CQ, Kasimumali A, Guo XJ, Lu RH, Xie KW, Zhu ML, Qian YY, Chen XH, Pang HH, Wang Q, et al. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease. <i>Nephrology</i> . 2020;25:230-238. doi: 10.1111/nep.13606 |
| 536 537 538 539 | 43. | Watson EL, Baker LA, Wilkinson TJ, Gould DW, Graham-Brown MPM, Major RW, Ashford RU, Philp A, Smith AC. Reductions in skeletal muscle mitochondrial mass are not restored following exercise training in patients with chronic kidney disease. <i>Faseb J</i> . 2020;34:1755-1767. doi: 10.1096/fj.201901936RR |
| 540 541 542 543 | 44. | Ryan TE, Yamaguchi DJ, Schmidt CA, Zeczycki TN, Shaikh SR, Brophy P, Green TD, Tarpey MD, Karnekar R, Goldberg EJ, et al. Extensive skeletal muscle cell mitochondriopathy distinguishes critical limb ischemia patients from claudicants. <i>JCI Insight</i> . 2018;3. doi: 10.1172/jci.insight.123235 |
| 544 545 546 | 45. | Hart CR, Layec G, Trinity JD, Kwon OS, Zhao J, Reese VR, Gifford JR, Richardson RS. Increased skeletal muscle mitochondrial free radical production in peripheral arterial disease despite preserved mitochondrial respiratory capacity. <i>Exp Physiol.</i> 2018. doi: 10.1113/EP086905 |
| 547 548 549 550 | 46. | Hart CR, Layec G, Trinity JD, Le Fur Y, Gifford JR, Clifton HL, Richardson RS. Oxygen availability and skeletal muscle oxidative capacity in patients with peripheral artery disease: implications from in vivo and in vitro assessments. <i>Am J Physiol-Heart C</i> . 2018;315:H897-H909. doi: 10.1152/ajpheart.00641.2017 |
| 551 552 | 47. | Park SY, Pekas EJ, Anderson CP, Kambis TN, Mishra PK, Schieber MN, Wooden TK, Thompson JR, Kim KS, Pipinos, II. Impaired microcirculatory function, mitochondrial |

| 553 554 555 | | respiration, and oxygen utilization in skeletal muscle of claudicating patients with peripheral artery disease. <i>Am J Physiol Heart Circ Physiol</i> . 2022;322:H867-H879. doi: 10.1152/ajpheart.00690.2021 |
|--------------------------|-----|---|
| 556 557 558 | 48. | Lindegard Pedersen B, Baekgaard N, Quistorff B. Mitochondrial dysfunction in calf muscles of patients with combined peripheral arterial disease and diabetes type 2. <i>International Angiology</i> . 2017;36:482-495. doi: 10.23736/S0392-9590.17.03824-X |
| 559 560 561 | 49. | Pipinos, II, Sharov VG, Shepard AD, Anagnostopoulos PV, Katsamouris A, Todor A, Filis KA, Sabbah HN. Abnormal mitochondrial respiration in skeletal muscle in patients with peripheral arterial disease. <i>J Vasc Surg.</i> 2003;38:827-832. |
| 562 563 564 | 50. | Pipinos, II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, Baxter BT, Lynch TG, Dodd SL. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. <i>Free Radic Biol Med.</i> 2006;41:262-269. doi: 10.1016/j.freeradbiomed.2006.04.003 |
| 565 566 567 568 | 51. | Picca A, Wohlgemuth SE, McDermott MM, Saini SK, Dayanidhi S, Zhang D, Xu S, Kosmac K, Tian L, Ferrucci L, et al. Mitochondrial Complex Abundance, Mitophagy Proteins, and Physical Performance in People With and Without Peripheral Artery Disease. <i>Journal of the American Heart Association</i> . 2023;12:e027088. doi: 10.1161/JAHA.122.027088 |
| 569 570 571 572 | 52. | McDermott MM, Peterson CA, Sufit R, Ferrucci L, Guralnik JM, Kibbe MR, Polonsky TS, Tian L, Criqui MH, Zhao L, et al. Peripheral artery disease, calf skeletal muscle mitochondrial DNA copy number, and functional performance. <i>Vasc Med.</i> 2018:1358863X18765667. doi: 10.1177/1358863X18765667 |
| 573 574 575 576 | 53. | Gonzalez-Freire M, Moore AZ, Peterson CA, Kosmac K, McDermott MM, Sufit RL, Guralnik JM, Polonsky T, Tian L, Kibbe MR, et al. Associations of Peripheral Artery Disease With Calf Skeletal Muscle Mitochondrial DNA Heteroplasmy. <i>Journal of the American Heart Association</i> . 2020;9:e015197. doi: 10.1161/JAHA.119.015197 |
| 577 578 579 | 54. | Flores-Opazo M, Kopinke D, Helmbacher F, Fernandez-Verdejo R, Tunon-Suarez M, Lynch GS, Contreras O. Fibro-adipogenic progenitors in physiological adipogenesis and intermuscular adipose tissue remodeling. <i>Mol Aspects Med.</i> 2024;97:101277. doi: 10.1016/j.mam.2024.101277 |
| 580 581 582 583 | 55. | Correa-de-Araujo R, Addison O, Miljkovic I, Goodpaster BH, Bergman BC, Clark RV, Elena JW, Esser KA, Ferrucci L, Harris-Love MO, et al. Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging. <i>Frontiers in physiology</i> . 2020;11. doi: ARTN 963 |
| 584 | | 10.3389/fphys.2020.00963 |
| 585 586 587 | 56. | Blitz NK, Collins KH, Shen KC, Schwartz K, Harris CA, Meyer GA. Infiltration of intramuscular adipose tissue impairs skeletal muscle contraction. <i>J Physiol-London</i> . 2020;598:2669-2683. doi: 10.1113/Jp279595 |

| 588 589 590 | 57. | Norris AM, Appu AB, Johnson CD, Zhou LY, McKellar DW, Renault MA, Hammers D, Cosgrove BD, Kopinke D. Hedgehog signaling via its ligand DHH acts as cell fate determinant during skeletal muscle regeneration. <i>Nature Communications</i> . 2023;14. doi: ARTN 3766 |
|--------------------------|-----|---|
| 591 | | 10.1038/s41467-023-39506-1 |
| 592 593 594 | 58. | Norris AM, Fierman KE, Campbell J, Pitale R, Shahraj M, Kopinke D. Studying intramuscular fat deposition and muscle regeneration: insights from a comparative analysis of mouse strains, injury models, and sex differences. <i>Skelet Muscle</i> . 2024;14:12. doi: 10.1186/s13395-024-00344-4 |
| 595 596 597 | 59. | Joe AWB, Yi L, Natarajan A, Le Grand F, So L, Wang J, Rudnicki MA, Rossi FMV. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. <i>Nature cell biology</i> . 2010;12:153-U144. doi: 10.1038/ncb2015 |
| 598 599 600 | 60. | Cheema B, Abas H, Smith B, O'Sullivan AJ, Chan M, Patwardhan A, Kelly J, Gillin A, Pang G, Lloyd B, et al. Investigation of skeletal muscle quantity and quality in end-stage renal disease. <i>Nephrology (Carlton)</i> . 2010;15:454-463. doi: 10.1111/j.1440-1797.2009.01261.x |
| 601 602 603 | 61. | Khattri RB, Kim K, Thome T, Salyers ZR, O'Malley KA, Berceli SA, Scali ST, Ryan TE. Unique Metabolomic Profile of Skeletal Muscle in Chronic Limb Threatening Ischemia. <i>Journal of Clinical Medicine</i> . 2021;10. doi: ARTN 548 |
| 604 | | 10.3390/jcm10030548 |
| 605 606 607 | 62. | Yang L, He Y, Li X. Physical function and all-cause mortality in patients with chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. <i>Int Urol Nephrol.</i> 2023;55:1219-1228. doi: 10.1007/s11255-022-03397-w |
| 608 609 610 | 63. | Ismaeel A, Franco ME, Lavado R, Papoutsi E, Casale GP, Fuglestad M, Mietus CJ, Haynatzki GR, Smith RS, Bohannon WT, et al. Altered Metabolomic Profile in Patients with Peripheral Artery Disease. <i>Journal of Clinical Medicine</i> . 2019;8. doi: ARTN 1463 |
| 611 | | 10.3390/jcm8091463 |
| 612 613 614 | 64. | Ho KJ, Ramirez JL, Kulkarni R, Harris KG, Helenowski I, Xiong L, Ozaki CK, Grenon SM. Plasma Gut Microbe-Derived Metabolites Associated with Peripheral Artery Disease and Major Adverse Cardiac Events. <i>Microorganisms</i> . 2022;10. doi: 10.3390/microorganisms10102065 |
| 615 616 617 618 | 65. | Razquin C, Ruiz-Canela M, Toledo E, Clish CB, Guasch-Ferre M, Garcia-Gavilan JF, Wittenbecher C, Alonso-Gomez A, Fito M, Liang L, et al. Circulating Amino Acids and Risk of Peripheral Artery Disease in the PREDIMED Trial. <i>Int J Mol Sci.</i> 2022;24. doi: 10.3390/ijms24010270 |
| 619 620 621 | 66. | Westbrook R, Chung T, Lovett J, Ward C, Joca H, Yang HL, Khadeer M, Tian J, Xue QL, Le AN, et al. Kynurenines link chronic inflammation to functional decline and physical frailty. <i>Jci Insight</i> . 2020;5. doi: ARTN 136091 |
| 622 | | 10.1172/jci.insight.136091 |
| 619 620 621 622 | 66. | Westbrook R, Chung T, Lovett J, Ward C, Joca H, Yang HL, Khadeer M, Tian J, Xue QL, Le AN, et al. Kynurenines link chronic inflammation to functional decline and physical frailty. <i>Jci Insight</i> . 2020;5. doi: ARTN 136091 10.1172/jci.insight.136091 |

| 623 624 | 67. | Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan's metabolites in exercise, inflammation, and mental health. <i>Science</i> . 2017;357. doi: 10.1126/science.aaf9794 |
|-------------------|-----|---|
| 625 626 627 | 68. | Xue C, Li G, Zheng Q, Gu X, Shi Q, Su Y, Chu Q, Yuan X, Bao Z, Lu J, et al. Tryptophan metabolism in health and disease. <i>Cell Metab</i> . 2023;35:1304-1326. doi: 10.1016/j.cmet.2023.06.004 |
| 628 | | |
| 629 | | |
| 630 | | |
| 631 | | |
| 632 | | |
| 633 | | |
| 634 | | |
| 635 | | |
| 636 | | |
| 637 | | |
| 638 | | |
| 639 | | |
| 640 | | |
| 641 | | |
| 642 | | |
| 643 | | |
| 644 | | |
| 645 | | |



655 TABLE 1: Participant Characteristics

| Physical Characteristics | Control (N=28) | PAD (N=46) | CKD (N=31) | PAD+CKD (N=18) | <i>P</i> value (χ^2 test or One-way |
|--------------------------|-------------------|-------------|---------------|-------------------|---|
| Physical Characteristics | | | | | ANOVA) |
| Mean age, y (SD) | 64.4 (12.0) | 64.5 (8.6) | 62.1 (12.4) | 65.5 (9.0) | 0.6869 |
| Female sex, n (%) | 8 (28.6) | 18 (39.1) | 13 (41.9) | 9 (50.0) | 0.5111 |
| Non-White, n (%) | 4 (14.3) | 10 (21.7) | 12 (38.7) | 6 (33.3) | 0.1366 |
| Non-Hispanic, n (%) | 26 (92.9) | 40 (87.0) | 31 (100.0) | 18 (100.0) | 0.0835 |
| BMI, kg/m² (SD) | 29.1 (6.3) | 27.6 (6.0) | 30.0 (6.9) | 28.3 (6.5) | 0.4777 |
| Disease Characteristics | | | | | |
| ABI (SD) | 1.00 (0.08) | 0.60 (0.26) | 1.04 (0.16) | 0.65 (0.24) | <0.0001 |
| TBI (SD) | 0.81 (0.17) | 0.36 (0.21) | 0.75 (0.15) | 0.34 (0.23) | <0.0001 |
| BUN, (mg/dL) (SD) | 15.8 (5.8) | 14.6 (5.2) | 35.0 (18.0) | 38.8 (25.6) | <0.0001 |
| Creatinine, (mg/dL) (SD) | 0.9 (0.2) | 0.9 (0.2) | 4.4 (2.5) | 3.9 (3.7) | <0.0001 |

| eGFR, (mL/min/1.73m ²) (SD) | 73.9 (19.3) | 70.2 (17.0) | 26.0 (12.2) | 30.1 (16.2) | <0.0001 |
|--|-------------------|-------------------------------|------------------|---------------|----------------|
| Tobacco use | 1 | | | | |
| Former smoker, n (%) | 18 (66.7) | 44 (95.7) | 9 (30.0) | 14 (77.8) | <0.0001 |
| Current smoker, n (%) | 7 (25.9) | 13 (28.3) | 1 (3.3) | 6 (33.3) | 0.0303 |
| Medical History | | | | | |
| Diabetes type I or II, n (%) | 9 (32.1) | 20 (43.5) | 16 (51.6) | 14 (77.8) | 0.0208 |
| Hypertension, n (%) | 18 (64.3) | 38 (82.6) | 30 (96.8) | 17 (94.4) | 0.0042 |
| Hyperlipidemia, n (%) | 17 (60.7) | 35 (76.1) | 18 (58.1) | 15 (83.3) | 0.1416 |
| Coronary artery disease, n (%) | 10 (35.7) | 23 (50.0) | 7 (22.6) | 6 (33.3) | 0.1028 |
| Congestive heart failure, n (%) | 6 (21.4) | 9 (19.6) | 9 (29.0) | 7 (38.9) | 0.3890 |
| Medication used | | | | | |
| Aspirin, n (%) | 15 (53.6) | 35 (76.1) | 13 (41.9) | 12 (66.7) | 0.0183 |
| ACE inhibitor, n (%) | 5 (17.9) | 17 (37.0) | 7 (22.6) | 4 (22.2) | 0.2581 |
| Angiotensin receptor blocker, n (%) | 4 (14.3) | 8 (17.4) | 8 (25.8) | 7 (38.9) | 0.1869 |
| Statin, n (%) | 21 (75.0) | 37 (80.4) | 22 (71.0) | 17 (94.4) | 0.2509 |
| Cilostazol, n (%) | 0 (0.0) | 14 (30.4) | 0 (0) | 4 (22.2) | 0.0006 |
| Beta Blocker, n (%) | 14 (50.0) | 25 (54.3) | 19 (61.3) | 15 (83.3) | 0.1201 |
| Anticoagulant, n (%) | 3 (10.7) | 17 (37.0) | 8 (25.8) | 8 (44.4) | 0.0430 |
| Antiplatelet, n (%) | 5 (17.9) | 12 (26.1) | 7 (22.6) | 2 (11.1) | 0.5764 |
| Abbreviations: BMI = body mass index: AB | l = ankle-brachia | l index [.] TBl = to | oe-brachial inde | x BUN = blood | urea nitrogen: |

eGFR = estimated glomerular filtration rate; ACE = angiotensin converting enzyme

656

657

658

659

661 FIGURE LEGENDS

662 Figure 1. Calf muscle strength and muscle fiber area is lowest in patients with PAD and CKD. (A) Calf

663 muscle strength in absolute and normalized to body weight (n=102). (B) Representative

664 immunofluorescence images of gastrocnemius muscle biopsies with fiber types and sizes labeled. (C)

Violin plots showing the cross-sectional areas of Type I (n=8816 myofibers) and Type II (n=8395)

666 myofibers in each patient group (n=63 patients). (**D**) Quantification of the percentage of Type I fibers

667 (n=63 patients). (E) Pearson correlation between calf muscle strength and mean myofiber area (both

Type I and II myofibers) (n=43 patients). Panel A was analyzed using a Kruskal-Wallis Test with Dunn's

test for pairwise comparisons. Panel C and D were analyzed using a one-way ANOVA with Tukey's post

670 hoc testing. Error bars represent the standard deviation.

671

672 Figure 2. Skeletal muscle mitochondrial function is significantly impaired in patients with CKD and

673 PAD+CKD. (A) Graphical depiction of mitochondrial analyses using permeabilized myofibers. (B)

674 Relationship between oxygen consumption (JO_2) and energy demand (ΔG_{ATP}) when mitochondria were

fueled with pyruvate, malate, and octanoylcarnitine. (C) Quantification of the conductance (the slope of

 JO_2 and ΔG_{ATP} relationship) (n=86 patients). (**D**) Citrate synthase activity in gastrocnemius muscle (n= 81

patients). (E) Relationship between mitochondrial hydrogen peroxide production (JH₂O₂) and energy

demand (ΔG_{ATP}) when mitochondria were fueled with pyruvate, malate, and octanoylcarnitin. (F)

679 Quantification of JH₂O₂ under state 2 (no energy demand) conditions (n=82 patients). (G) Quantification

 $of JH_2O_2$ with mitochondrial fueled with succinate followed by inhibition of the matrix antioxidant

681 systems (with AF/BCNU) (n=85 patients). Analyzed via two-way ANOVA with Tukey's post hoc. (H)

- 682 Representative images and quantification of succinate dehydrogenase (SDH) activity in muscle sections
- 683 (n= patients.

Panels C, D, F, and H were analyzed with a one-way ANOVA with Tukey's post hoc. Error bars representthe standard deviation.

686

Figure 3. CKD profoundly impacts the plasma metabolome independent of PAD. (A) Targeted plasma metabolomic quantification of uremic toxins (n=97 patients). Analysis done using one-way ANOVA with Tukey's post hoc. (**B**) Graphic of experimental design and overall metabolite detection for untargeted (global) metabolomics in patient plasma. (**C**) Principal component analysis demonstrates separation between CKD and non-CKD patients, independent of PAD. (**D**) A heatmap with hierarchical clustering of metabolites and patients. (**E**) Venn diagram showing significant metabolite differences across group comparisons. Error bars represent the standard deviation.

694

Figure 4. Uremic toxin levels have an inverse relationship with calf muscle mitochondrial function and
 strength. (A) Pearson correlations between OXPHOS conductance and L-Kynurenine, L-Kyn/Trp ratio,

and indoxyl sulfate levels (n=81 patients). (B) Pearson correlations between calf muscle strength and LKynurenine, L-Kyn/Trp ratio, and indoxyl sulfate levels (n=72 patients). Statistical analyses performed
using two-tailed Pearson correlation.

700

701 Figure 5. Whole muscle and single nucleus RNA sequencing identify mitochondrial deficiency and 702 cytoplasmic translation defects in patients with PAD+CKD. (A) RNA sequencing on total RNA from the 703 gastrocnemius was performed (n=88 patients). Partial least squares discriminant analysis (PLS-DA) 704 revealed clear separation between PAD and PAD+CKD patients. (B) Volcano plot of gene expression 705 shows differentially expressed genes in PAD and PAD+CKD patients. (C) Gene set enrichment analysis in 706 significantly upregulated and downregulated genes between PAD and PAD+CKD patients. (D) Single 707 nucleus RNA sequencing was performed on gastrocnemius muscle specimens from 20 PAD and 12 708 PAD+CKD patients. UMAPs presented by group and by cell types are shown. (E) Percentage of nuclei 709 within each cluster determined by group. (F) Dotplots of the top 4 marker genes for each cell type. (G) 710 UMAPs of the subclustering of myofiber nuclei by group and type. (H) Venn diagrams shown 711 differentially expressed genes by myonuclei type. (I) UMAPs showing the mitochondrial gene module score for each nuclei demonstrated the mitochondrial deficiency in PAD+CKD muscles. (J) Gene set 712 713 enrichment analysis results for myonuclei populations. The x-axis is the normalized enrichment score

and the values for each bar are the adjusted *P*-values.

715

- 716 Figure 6. Fibro-adipogenic progenitor cells are uniquely remodeled in muscles from patients with
- 717 **PAD+CKD.** (A) UMAPs of the subclustering of FAPs presented by group and by subpopulation type are
- shown. (**B**) Donut plots showing the abundance of subpopulations of FAPs in both groups. (**C**) Ranked
- 719 significant ligand-receptor communications for relative information flow between AHR^{fl/fl} and AHR^{mKO}
- muscles. (D) Trajectory inference in FAPs showed three distinct fates in PAD+CKD. (E) Feature plots
- showing normalized gene expression levels for inflammatory, pro-fibrotic, and adipogenic genes. (F)
- 722 Gene expression changes across those three fates across pseudotime for both groups.

723

724 Figure 7. CellChat analysis predicts changes in intercellular communication of PAD+CKD patients. (A)

Circle plots showing the overall intercellular communication occurring in non-PAD and PAD. Circle sizes
 represent the number of cells and edge width represents communication probability. (B) Comparison of

- outgoing and incoming interaction strengths for all cells type in non-PAD and PAD. (C) Ranked significant
- 728 ligand-receptor communications for relative information flow between non-PAD and PAD muscles. (D)
- 729 Circle plots for FGF signaling communication in non-PAD and PAD.
- 730
- 731
- 732

| 733 | |
|--|---|
| 734 | |
| 735 | |
| 736 | |
| 737 | |
| 738 | |
| 739 | |
| 735 | |
| 740 | |
| /41 | NOVELTY AND SIGNIFICANCE |
| 742 | |
| 743 | What is known? |
| 744 745 746 747 748 749 | Peripheral artery disease (PAD) patients with chronic kidney disease (CKD) have poorer health outcomes and increased risk for adverse limb events and mortality compared with patients with normal kidney function. The accumulation of uremic toxins in CKD have been associated with adverse limb events in patients that have PAD. |
| 750 | What new information does this article contribute? |
| 751 752 753 754 755 756 757 758 | Patients with PAD and CKD have significantly lower calf muscle strength, muscle fiber size, and mitochondrial function compared to PAD patients with normal kidney function. CKD, but not PAD alone, has a significant impact on the plasma metabolome. Uremic toxins such as indoxyl sulfate and L-Kynurenine have significant inverse relationships with calf muscle strength and mitochondrial function. Bulk and single nucleus RNA sequencing reveals a mitochondrial deficiency in myofibers and pro-fibrotic/pro-adipogenic differentiation states of fibro-adipogenic progenitor cells in patients with PAD and CKD. |
| 760 761 762 763 | There is overwhelming evidence that PAD patients with CKD have significantly higher risk of major adverse limb events and death compared to PAD patients without CKD. Moreover, having CKD increases the likelihood that endovascular and open revascularization procedures fail in patients with PAD. Skeletal muscle pathologies have been shown to play important roles in both PAD and CKD |

- real independently. Because skeletal muscle function is a strong predictor of morbidity and mortality, it is
- important to understand how CKD exacerbates the myopathy of PAD to improve medical management
- in these patients. In a cohort of 123 patients, calf muscle strength was lowest in PAD patients with CKD,
- although both those PAD and CKD alone were also significantly weaker than non-PAD and non-CKD
- controls. Muscle fiber atrophy was also evident and muscle fiber size correlated with calf muscle
- strength. Using calf muscle biopsies, we found that mitochondrial function was significantly impaired in
- patients with CKD and those with PAD+CKD. Significant inverse correlations were found between uremic
- toxins and muscle strength and mitochondrial function. Bulk and single nucleus RNA sequencing
- revealed the wide-ranging impact of CKD on the muscle transcriptome in patients with PAD. In
- summary, this study establishes CKD as a major driver of skeletal muscle pathology in patients with PAD.
- 774
- 775
- ____
- 776
- 777
- 778
- 779
- ,,,,
- 780
- 781
- 782



786 Figure 1. Calf muscle strength and muscle fiber area is lowest in patients with PAD and CKD. (A) Calf 787 muscle strength in absolute and normalized to body weight (n=102). (B) Representative 788 immunofluorescence images of gastrocnemius muscle biopsies with fiber types and sizes labeled. (C) 789 Violin plots showing the cross-sectional areas of Type I (n=8816 myofibers) and Type II (n=8395) 790 myofibers in each patient group (n=63 patients). (**D**) Quantification of the percentage of Type I fibers 791 (n=63 patients). (E) Pearson correlation between calf muscle strength and mean myofiber area (both 792 Type I and II myofibers) (n=43 patients). Panel A was analyzed using a Kruskal-Wallis Test with Dunn's 793 test for pairwise comparisons. Panel C and D were analyzed using a one-way ANOVA with Tukey's post 794 hoc testing. Error bars represent the standard deviation.

795

783

784



797

798





- 801 **PAD+CKD.** (**A**) Graphical depiction of mitochondrial analyses using permeabilized myofibers. (**B**)
- 802 Relationship between oxygen consumption (JO_2) and energy demand (ΔG_{ATP}) when mitochondria were 803 fueled with pyruvate, malate, and octanoylcarnitine. (**C**) Quantification of the conductance (the slope of
- JO_2 and ΔG_{ATP} relationship) (n=86 patients). (**D**) Citrate synthase activity in gastrocnemius muscle (n= 81
- patients). (E) Relationship between mitochondrial hydrogen peroxide production (JH_2O_2) and energy
- 806 demand (ΔG_{ATP}) when mitochondria were fueled with pyruvate, malate, and octanoylcarnitin. (F)

- 807 Quantification of JH₂O₂ under state 2 (no energy demand) conditions (n=82 patients). (G) Quantification
- 00 of JH_2O_2 with mitochondrial fueled with succinate followed by inhibition of the matrix antioxidant
- systems (with AF/BCNU) (n=85 patients). Analyzed via two-way ANOVA with Tukey's post hoc. (H)
- 810 Representative images and quantification of succinate dehydrogenase (SDH) activity in muscle sections
- 811 (n= patients.
- 812 Panels C, D, F, and H were analyzed with a one-way ANOVA with Tukey's post hoc. Error bars represent
- 813 the standard deviation.



814

815

Figure 3. CKD profoundly impacts the plasma metabolome independent of PAD. (A) Targeted plasma
metabolomic quantification of uremic toxins (n=97 patients). Analysis done using one-way ANOVA with
Tukey's post hoc. (B) Graphic of experimental design and overall metabolite detection for untargeted
(global) metabolomics in patient plasma. (C) Principal component analysis demonstrates separation
between CKD and non-CKD patients, independent of PAD. (D) A heatmap with hierarchical clustering of
metabolites and patients. (E) Venn diagram showing significant metabolite differences across group
comparisons. Error bars represent the standard deviation.

823

824





840 Figure 4. Uremic toxin levels have an inverse relationship with calf muscle mitochondrial function and

841 strength. (A) Pearson correlations between OXPHOS conductance and L-Kynurenine, L-Kyn/Trp ratio,

and indoxyl sulfate levels (n=81 patients). (B) Pearson correlations between calf muscle strength and L-

- 843 Kynurenine, L-Kyn/Trp ratio, and indoxyl sulfate levels (n=72 patients). Statistical analyses performed
- 844 using two-tailed Pearson correlation.



863

864 Figure 5. Whole muscle and single nucleus RNA sequencing identify mitochondrial deficiency and cytoplasmic translation defects in patients with PAD+CKD. (A) RNA sequencing on total RNA from the 865 866 gastrocnemius was performed (n=88 patients). Partial least squares discriminant analysis (PLS-DA) 867 revealed clear separation between PAD and PAD+CKD patients. (B) Volcano plot of gene expression 868 shows differentially expressed genes in PAD and PAD+CKD patients. (C) Gene set enrichment analysis in 869 significantly upregulated and downregulated genes between PAD and PAD+CKD patients. (D) Single nucleus RNA sequencing was performed on gastrocnemius muscle specimens from 20 PAD and 12 870 871 PAD+CKD patients. UMAPs presented by group and by cell types are shown. (E) Percentage of nuclei within each cluster determined by group. (F) Dotplots of the top 4 marker genes for each cell type. (G) 872 873 UMAPs of the subclustering of myofiber nuclei by group and type. (H) Venn diagrams shown 874 differentially expressed genes by myonuclei type. (I) UMAPs showing the mitochondrial gene module 875 score for each nuclei demonstrated the mitochondrial deficiency in PAD+CKD muscles. (J) Gene set 876 enrichment analysis results for myonuclei populations. The x-axis is the normalized enrichment score 877 and the values for each bar are the adjusted *P*-values. 878

879





- Figure 6. Fibro-adipogenic progenitor cells are uniquely remodeled in muscles from patients with
- 886 PAD+CKD. (A) UMAPs of the subclustering of FAPs presented by group and by subpopulation type are

- shown. (B) Donut plots showing the abundance of subpopulations of FAPs in both groups. (C) Ranked
- 888 significant ligand-receptor communications for relative information flow between AHR^{fl/fl} and AHR^{mKO}
- 889 muscles. (**D**) Trajectory inference in FAPs showed three distinct fates in PAD+CKD. (**E**) Feature plots
- 890 showing normalized gene expression levels for inflammatory, pro-fibrotic, and adipogenic genes. (F)
- 891 Gene expression changes across those three fates across pseudotime for both groups.



892

893

894 Figure 7. CellChat analysis predicts changes in intercellular communication of PAD+CKD patients. (A)

895 Circle plots showing the overall intercellular communication occurring in non-PAD and PAD. Circle sizes

represent the number of cells and edge width represents communication probability. (B) Comparison of

- 897 outgoing and incoming interaction strengths for all cells type in non-PAD and PAD. (C) Ranked significant
- 898 ligand-receptor communications for relative information flow between non-PAD and PAD muscles. (D)
- 899 Circle plots for FGF signaling communication in non-PAD and PAD.